Adults with diabetes mellitus frequently develop macrovascular complications. Vascular disease is a frequent cause of morbidity and mortality among patients with diabetes. Diabetes and vascular diseases remain among the most common causes of death in the United States. A number of clinical trials and practice guidelines have been published addressing the management of macrovascular complications. The cornerstone of preventing or delaying the progression of macrovascular complications of diabetes is aggressive management of hypertension and cholesterol. Angiotensin-converting enzyme inhibitors have proven effective in managing hypertension and avoiding other complications of diabetes. The body of evidence for angiotensin receptor blockers is growing in this area as well. Statins have been repeatedly proven to be the first-line agents in the management of dyslipidemia. Lifestyle modification strategies and antiplatelet therapy also remain essential. This review will focus on the role of newer diagnostic techniques, clinical trial evidence, and appropriate pharmacotherapy for macrovascular complications of diabetes.
Kung HC, Hoyert DL, Xu JQ, Murphy SLDeaths: final data for 2005. National vital statistics reports. Vol 56. Hyattsville, MD: National Center for Health Statistics ; 2008. Available at: http://www.cdc.gov/nchs/data/nvsr/nvsr56/nvsr56_10.pdf. Accessed June 6, 2008.
2.
National Institute of Diabetes and Digestive and Kidney Diseases.National Diabetes Statistics Fact Sheet: General Information and National Estimates on Diabetes in the United States, 2005. Bethesda, MD: U.S. Department of Health and Human Services, National Institute of Health; 2005. Available at: http://diabetes.niddk.nih.gov/dm/pubs/statistics/index.htm#12 . Accessed June 6, 2008.
3.
Grundy SM, Cleeman JI, Merz CN, et al, National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association.Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation . 2004;110:227-239.
4.
Eckel RH, Wassef M., Chait A., et al. Prevention Conference VI: diabetes and cardiovascular disease: writing group II: pathogenesis of atherosclerosis in diabetes. Circulation. 2002;105:e138-e143.
5.
Ross R.The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362:801-809.
6.
Chobanian AVVascular effects of systemic hypertension. Am J Cardiol.1992;69:3E-7E.
7.
Franco OH, Steyerberg EW, Hu FB, Mackenbach J., Nusselder W.Associations of diabetes mellitus with total life expectancy and life expectancy with and without cardiovascular disease. Arch Intern Med. 2007;167: 1145-1151.
8.
Sigal RJ, Kenny GP, Wasserman DH, Castaneda-Sceppa C.Physical activity/exercise and type 2 diabetes. Diabetes Care . 2004;27:2518-2539.
9.
Franz MJ, Bantle JP, Beebe CA, et al. Nutrition principles and recommendations in diabetes. Diabetes Care. 2004;27(suppl 1):S36-S46.
10.
Buse JB, Ginsberg HN, Bakris GL, et al, American Heart Association; American Diabetes Association.Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care. 2007;30:162-172.
11.
Lichtenstein AH, Appel LJ, Brands M., et al, American Heart Association Nutrition Committee.Diet and lifestyle recommendations revision 2006: a scientific statement from the American Heart Association Nutrition Committee. Circulation. 2006;114:82-96.
12.
Vollmer WM, Sacks FM, Ard J., et al, DASH-Sodium Trial Collaborative Research Group.Effects of diet and sodium intake on blood pressure: subgroup analysis of the DASH-sodium trial. Ann Intern Med.2001;135: 1019-1028.
13.
Stern L., Iqbal N., Seshadri P., et al. The effects of low-carbohydrate versus conventional weight loss diets in severely obese adults: one-year follow-up of a randomized trial. Ann Intern Med. 2004;140:778-785.
14.
Foster GD, Wyatt HR, Hill JO, et al. A randomized trial of a low-carbohydrate diet for obesity. N Engl J Med. 2003;348:2082-2090.
15.
Chobanian AV , Bakris GL, Black HR, et al, National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee.The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560-2572.
16.
National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143-3421.
17.
Maguire TA, McElnay JC, Drummond A.A randomized controlled trial of a smoking cessation intervention based in community pharmacies. Addiction. 2001;96: 325-331.
18.
University of California, San Francisco.Rx for change. Clinician assisted tobacco cessation. Available at: http://rxforchange.ucsf.edu/. Accessed June 30, 2008 .
19.
Silagy C., Lancaster T., Stead L., Mant D., Fowler G.Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev.2004:CD000146.
20.
Lam W., Sze PC, Sacks HS, Chalmers TCMeta-analysis of randomised controlled trials of nicotine chewing-gum. Lancet. 1987;2:27-30.
21.
Joseph AM, Norman SM, Ferry LH, et al. The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease. N Engl J Med. 1996;335: 1792-1798.
22.
Paluck EC, McCormack JP, Ensom MH, Levine M., Soon JA, Fielding DWOutcomes of bupropion therapy for smoking cessation during routine clinical use. Ann Pharmacother. 2006;40:185-190.
23.
Simon JA, Duncan C., Carmody TP, Hudes ESBupropion for smoking cessation: a randomized trial. Arch Intern Med. 2004;164:1797-1803.
24.
Tonstad S., Farsang C., Klaene G., et al. Bupropion SR for smoking cessation in smokers with cardiovascular disease: a multicentre, randomised study. Eur Heart J. 2003;24:946-955.
25.
Tonstad S., Tonnesen P., Hajek P., Williams KE, Billing CB, Reeves KREffect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA. 2006;296:64-71.
26.
Jorenby DE, Hays JT, Rigotti NA, et al, Varenicline Phase 3 Study Group.Efficacy of varenicline, an alpha4-beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA. 2006;296:56-63.
27.
Gonzales D. , Rennard SI, Nides M., et al, Varenicline Phase 3 Study Group.Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA. 2006;296:47-55.
28.
U.S. Food and Drug Administration.Center for drug evaluation and research.Chantix Information: May 16, 2008. Available at: http://www.fda.gov/cder/drug/infopage/varenicline/default.htm. Accessed June 30, 2008.
29.
Anthonisen NR, Skeans MA, Wise RA, Manfreda J., Kanner RE, Connett JEThe effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med.2005;142:233-239.
30.
Haire-Joshu D., Glasgow RE, Tibbs TLSmoking and diabetes. Diabetes Care. 2004;27(suppl 1):S74-S75.
31.
Rosendorff C., Black HR, Cannon CP, et al, American Heart Association Council for High Blood Pressure Research; American Heart Association Council on Clinical Cardiology; American Heart Association Council on Epidemiology and Prevention.Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation. 2007;115: 2761-2788.
32.
American Diabetes Association.Standards of medical care in diabetes-2008. Diabetes Care . 2008;31(suppl 1):S12-S54.
Vivian EMImproving blood pressure control in a pharmacist-managed hypertension clinic . Pharmacotherapy. 2002;22:1533-1540.
35.
Lee JK, Grace KA, Taylor AJEffect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol: a randomized controlled trial. JAMA. 2006;296:2563-2571.
36.
Von Muenster SJ, Carter BL, Weber CA, et al. Description of pharmacist interventions during physician-pharmacist co-management of hypertension. Pharm World Sci. 2008;30:128-135.
37.
Green BB, Cook AJ, Ralston JD, et al. Effectiveness of home blood pressure monitoring, Web communication, and pharmacist care on hypertension control: a randomized controlled trial . JAMA. 2008;299:2857-2867.
38.
Re RNTissue renin angiotensin systems. Med Clin North Am. 2004;88:19-38.
39.
Hall JEHistorical perspective of the renin-angiotensin system. Mol Biotechnol. 2003;24:27-39.
40.
Pool JL, Schmieder RE, Azizi M., et al. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. Am J Hypertens . 2007;20:11-20.
41.
Jordan J., Engeli S., Boye SW, Le Breton S., Keefe DLDirect renin inhibition with aliskiren in obese patients with arterial hypertension . Hypertension. 2007;49: 1047-1055.
42.
Strasser RH , Puig JG, Farsang C., Croket M., Li J., van Ingen H.A comparison of the tolerability of the direct renin inhibitor aliskiren and lisinopril in patients with severe hypertension . J Hum Hypertens. 2007;21: 780-787.
43.
Verdecchia P., Calvo C., Mockel V., Keeling L., Satlin A.Safety and efficacy of the oral direct renin inhibitor aliskiren in elderly patients with hypertension. Blood Press. 2007;16:381-391.
44.
Uresin Y., Taylor AA, Kilo C., et al. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension . J Renin Angiotensin Aldosterone Syst. 2007 ;8: 190-198.
45.
Andersen K. , Weinberger MH, Egan B., et al. Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial. J Hypertens. 2008;26: 589-599.
46.
Parving HH, Persson F., Lewis JB, Lewis EJ, Hollenberg NKAliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med. 2008;358: 2433-2446.
47.
Drugstore.com. Tekturna 150 mg. Available at: http://www.drugstore.com/. Accessed June 30, 2008 .
48.
Lamb E.Top 200 prescription drugs of 2007. Pharmacy Times. 2008;74:20-23.
49.
Mogensen CE , Neldam S., Tikkanen I., et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ. 2000;321:1440-1444.
50.
Lewis EJ, Hunsicker LG, Clarke WR, et al, Collaborative Study Group.Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med.2001;345:851-860.
51.
Dahlof B., Devereux RB, Kjeldsen SE, et al, LIFE Study Group.Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995-1003.
52.
Dickstein K. , Kjekshus J., OPTIMAAL Steering Committee of the OPTIMAAL Study Group.Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet. 2002;360:752-760.
53.
Brenner BM, Cooper ME, de Zeeuw D., et al, RENAAL Study Investigators.Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med.2001;345:861-869.
54.
Lindholm LH , Ibsen H., Dahlof B., et al, LIFE Study Group.Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet . 2002;359: 1004-1010.
55.
Nakao N., Yoshimura A., Morita H., Takada M., Kayano T., Ideura T.Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet. 2003;361:117-124.
56.
Parving HH, Lehnert H., Brochner-Mortensen J., Gomis R., Andersen S., Arner P.The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345:870-878.
57.
Yusuf S., Teo KK, Pogue J., et al, ONTARGET Investigators.Telmisartan, ramipril, or both in patients at high risk for vascular events . N Engl J Med. 2008;358: 1547-1559.
58.
McMurray JJ , Ostergren J., Swedberg K., et al, CHARM Investigators and Committees.Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet. 2003;362:767-771.
59.
Granger CB, McMurray JJ, Yusuf S., et al, CHARM Investigators and Committees.Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet. 2003;362:772-776.
60.
Cohn JN, Tognoni G.A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:1667-1675.
61.
National High Blood Pressure Education Program Working Group report on hypertension in diabetes. Hypertension. 1994;23:145-158; discussion 159-160.
62.
American Diabetes Association: clinical practice recommendations 1997. Diabetes Care. 1997;20(suppl 1): S1-S70.
63.
Lewis EJ, Hunsicker LG, Bain RP, Rohde RDThe effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med.1993;329:1456-1462.
64.
Maschio G., Alberti D., Janin G., et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med.1996;334:939-945.
65.
Patel A., ADVANCE Collaborative Group.Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007;370:829-840.
66.
Hansson L., Lindholm LH, Niskanen L., et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet. 1999;353: 611-616.
67.
Tatti P., Pahor M., Byington RP, et al. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care. 1998;21:597-603.
68.
Yusuf S., Sleight P., Pogue J., Bosch J., Davies R., Dagenais G.Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med.2000;342: 145-153.
69.
Hansson L., Lindholm LH, Ekbom T., et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet. 1999;354:1751-1756.
70.
Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group. BMJ. 1998;317:713-720.
71.
Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet. 2000;355:253-259.
Haffner SMManagement of dyslipidemia in adults with diabetes. Diabetes Care. 2003;26(suppl 1):S83-S86.
74.
Friedewald WT, Levy RI, Fredrickson DSEstimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge . Clin Chem. 1972;18:499-502.
75.
Sniderman ADLow-density lipoprotein lowering in type 2 diabetes mellitus: how to know how low to go. Curr Opin Endocrinol Diabetes Obes. 2007;14:116-123.
76.
Cromwell WC , Otvos JDLow-density lipoprotein particle number and risk for cardiovascular disease. Curr Atheroscler Rep. 2004;6:381-387.
77.
El Harchaoui K., van der Steeg WA, Stroes ES, et al. Value of low-density lipoprotein particle number and size as predictors of coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study. J Am Coll Cardiol. 2007;49:547-553.
78.
Otvos JD, Collins D., Freedman DS, et al. Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial . Circulation. 2006;113:1556-1563.
79.
Blake GJ, Otvos JD, Rifai N., Ridker PMLow-density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women. Circulation. 2002;106:1930-1937.
80.
Rosenson RS , Otvos JD, Freedman DSRelations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-I) trial. Am J Cardiol. 2002;90:89-94.
81.
Kuller L., Arnold A., Tracy R., et al. Nuclear magnetic resonance spectroscopy of lipoproteins and risk of coronary heart disease in the cardiovascular health study. Arterioscler Thromb Vasc Biol. 2002;22:1175-1180.
82.
Lamarche B. , Tchernof A., Moorjani S., et al. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Circulation . 1997;95:69-75.
83.
Brunzell JD , Davidson M., Furberg CD, et al, American Diabetes Association; American College of Cardiology Foundation.Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care.2008;31:811-822.
84.
Sniderman AD , Furberg CD, Keech A., et al. Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment. Lancet . 2003;361:777-780.
85.
Walldius G. , Jungner I., Holme I., Aastveit AH, Kolar W., Steiner E.High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet. 2001;358:2026-2033.
86.
Lamarche B. , Moorjani S., Lupien PJ, et al. Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Quebec cardiovascular study. Circulation. 1996;94:273-278.
87.
van der Steeg WA, Boekholdt SM, Stein EA, et al. Role of the apolipoprotein B-apolipoprotein A-I ratio in cardiovascular risk assessment: a case-control analysis in EPIC-Norfolk . Ann Intern Med. 2007;146:640-648.
88.
Ingelsson E. , Schaefer EJ, Contois JH, et al. Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. JAMA. 2007;298: 776-785.
89.
Ridker PM, Rifai N., Cook NR, Bradwin G., Buring JENon-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women . JAMA. 2005;294:326-333.
90.
AACE Diabetes Mellitus Clinical Practice Guidelines Task Force.American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus . Endocr Pract. 2007;13(suppl 1):1-68.
91.
Collins R., Armitage J., Parish S., Sleigh P., Peto R.MRC/ BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003;361:2005-2016.
92.
Pedersen TR, Faergeman O., Kastelein JJ, et al, Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group.High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA. 2005;294:2437-2445.
93.
Keech A., Simes RJ, Barter P., et al, FIELD study investigators.Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366:1849-1861.
94.
LaRosa JC, Grundy SM, Waters DD, et al, Treating to New Targets (TNT) Investigators.Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med.2005;352:1425-1435.
95.
Colhoun HM, Betteridge DJ, Durrington PN, et al, CARDS investigators.Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364:685-696.
96.
AstraZeneca International.Crestor outcomes study JUPITER closes early due to unequivocal evidence of benefit [press release: March 31, 2008]. Available at: http://www.astrazeneca.com/pressrelease/5385.aspx. Accessed June 6, 2008.
97.
ClinicalTrials.gov. JUPITER-Crestor 20 mg versus placebo in prevention of cardiovascular events. NCT 00239681. Available at: http://clinicaltrials.gov/ct2/show/NCT00239681. Accessed June 6, 2008.
98.
Crestor [package insert]. Wilmington, DE : AstraZeneca Pharmaceuticals; 2007 .
Altoprev [package insert]. Fort Lauderdale, FL: Andrx Pharmaceuticals, Inc.; 2005.
104.
Final report on the aspirin component of the ongoing Physicians' Health Study. Steering Committee of the Physicians' Health Study Research Group. N Engl J Med. 1989;321:129-135.
105.
Peto R., Gray R., Collins R., et al. Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J. (Clin Res Ed).1988 ;296:313-316.
106.
de Gaetano G., Collaborative Group of the Primary Prevention Project.Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project. Lancet . 2001;357:89-95.
107.
Hansson L. , Zanchetti A., Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group . Lancet. 1998;351:1755-1762.
108.
Bhatt DL, Marso SP, Hirsch AT, Ringleb PA, Hacke W., Topol EJAmplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. Am J Cardiol. 2002;90:625-628.
109.
The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993;329:977-986.
110.
Stratton IM , Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321: 405-412.
111.
Selvin E., Marinopoulos S., Berkenblit G., et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med. 2004 ;141:421-431.
112.
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group . Lancet. 1998;352:837-853.
113.
Patel A., MacMahon S., Chalmers J., et al, ADVANCE Collaborative Group.Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560-2572.
114.
Gerstein HC , Miller ME, Byington RP, et al, Action to Control Cardiovascular Risk in Diabetes Study Group.Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med . 2008;358:2545-2559.
